Kaniksha Shekhar Desai, MD
Endocrinology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Desai’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A145417 · Current
Licensed to practise in California · since 2016 · expires 2026-10-31 · Wake Forest School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$39,934
Medicare paid this office $39,934 for 179 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 95 | $23,448 | $150 |
| Long return visit (40+ min) | 29 | $5,028 | $117 |
| Return visit (30+ min) | 24 | $2,920 | $101 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 98 | $1,977 | $15 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 71 | $1,106 | $13 |
Who their Medicare patients are
179 Original Medicare patients in 2024. Average age 71 · Under 65 13% · 85 and older 8% · Women 67% · Also on Medicaid 23% · Health risk score 1.73. Above the middle of the specialty; the typical endocrinology clinician is at 1.46.
Conditions among them: High blood pressure 66% · Chronic kidney disease 31% · Diabetes 26% · Coronary heart disease 22% · Depression 21% · Cancer 20% · Atrial fibrillation 15% · Heart failure 14% · COPD 9% · Dementia 8% · Stroke 6%.
The office billed $226,967, Medicare allowed $56,307 and paid $39,934; for 520 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 179 | 520 | 71 | 1.73 | $226,967 | $39,934 |
| 2023 | 164 | 315 | 72 | 1.38 | $226,399 | $33,970 |
| 2022 | 207 | 348 | 71 | 1.50 | $221,288 | $36,600 |
| 2021 | 194 | 352 | 71 | 1.40 | $227,169 | $39,279 |
| 2020 | 168 | 309 | 70 | 1.88 | $148,501 | $25,551 |
| 2019 | 130 | 209 | 69 | 2.00 | $31,076 | $16,982 |
| 2018 | 192 | 330 | 69 | 1.81 | $45,517 | $24,837 |
| 2017 | 205 | 370 | 69 | 1.99 | $78,791 | $27,756 |
| 2016 | 246 | 540 | 66 | 1.46 | $180,891 | $31,509 |
| 2015 | 163 | 192 | 70 | 1.49 | $40,489 | $14,319 |
| 2014 | 215 | 285 | 70 | 1.50 | $42,486 | $26,808 |
| 2013 | 121 | 151 | 69 | 1.41 | $25,509 | $15,867 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Long return visit (40+ min) | 111 | $27,196 | $119 |
| Return visit (30+ min) | 40 | $3,906 | $78 |
| New patient visit (60+ min) | 11 | $1,670 | $152 |
2022: 4 services
| Long return visit (40+ min) | 131 | $25,766 | $117 |
| Return visit (30+ min) | 42 | $3,832 | $80 |
| New patient visit (60+ min) | 17 | $2,255 | $133 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,624 | $65 |
2021: 3 services
| Long return visit (40+ min) | 114 | $22,938 | $116 |
| New patient visit (60+ min) | 35 | $5,853 | $167 |
| Return visit (30+ min) | 44 | $4,611 | $81 |
2020: 3 services
| Long return visit (40+ min) | 66 | $9,423 | $94 |
| Return visit (30+ min) | 90 | $7,151 | $63 |
| New patient visit (60+ min) | 15 | $2,357 | $157 |
2019: 2 services
| Long return visit (40+ min) | 57 | $8,123 | $96 |
| Return visit (30+ min) | 66 | $4,982 | $62 |
2018: 6 services
| Return visit (30+ min) | 99 | $8,332 | $60 |
| Long return visit (40+ min) | 41 | $4,734 | $91 |
| New patient visit (45+ min) | 20 | $2,190 | $110 |
| New patient visit (60+ min) | 13 | $1,957 | $151 |
| Return visit (30+ min) | 22 | $1,581 | $63 |
| Short return visit (20+ min) | 18 | $785 | $39 |
2017: 6 services
| Return visit (30+ min) | 89 | $7,717 | $59 |
| New patient visit (45+ min) | 60 | $6,330 | $105 |
| Long return visit (40+ min) | 45 | $5,883 | $95 |
| New patient visit (60+ min) | 20 | $3,006 | $150 |
| Short return visit (20+ min) | 35 | $1,324 | $34 |
| New patient visit (30+ min) | 15 | $908 | $61 |
2016: 7 services
| Return visit (30+ min) | 133 | $11,188 | $69 |
| Long return visit (40+ min) | 73 | $6,749 | $81 |
| Short return visit (20+ min) | 49 | $2,395 | $45 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 23 | $2,209 | $96 |
| New patient visit (60+ min) | 13 | $1,819 | $140 |
| Hemoglobin a1c level | 78 | $1,653 | $12 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $720 | $51 |
2015: 5 services
| Long return visit (40+ min) | 51 | $5,022 | $90 |
| Return visit (30+ min) | 59 | $4,421 | $71 |
| New patient visit (30+ min) | 28 | $2,023 | $72 |
| Short return visit (20+ min) | 16 | $714 | $45 |
| Hemoglobin a1c level | 12 | $153 | $13 |
2014: 6 services
| Long return visit (40+ min) | 78 | $8,738 | $100 |
| New patient visit (45+ min) | 43 | $5,283 | $123 |
| Return visit (30+ min) | 54 | $5,053 | $74 |
| New patient visit (60+ min) | 31 | $4,574 | $148 |
| Short return visit (20+ min) | 31 | $1,676 | $48 |
| New patient visit (30+ min) | 20 | $1,452 | $73 |
2013: 5 services
| Long return visit (40+ min) | 62 | $6,692 | $100 |
| New patient visit (45+ min) | 37 | $4,592 | $124 |
| New patient visit (60+ min) | 11 | $1,689 | $154 |
| Return visit (30+ min) | 17 | $1,355 | $80 |
| New patient visit (30+ min) | 11 | $862 | $78 |
Medicaid work
$4,677 in 2024
Medicaid paid $4,677 for 41 billed services this clinician did in 2024, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 41 | $4,677 |
| 2024 | 41 | 1 | 15 | $4,677 |
| 2023 | 119 | 1 | 18 | $8,001 |
| 2022 | 134 | 1 | 18 | $10,031 |
| 2021 | 140 | 1 | 24 | $9,114 |
| 2020 | 38 | 1 | 13 | $2,676 |
| 2019 | 37 | 1 | 13 | $1,489 |
| 2018 | 67 | 1 | 15 | $2,820 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 119 | $8,001 |
2022
| Long return visit (40+ min) | 134 | $10,031 |
2021
| Long return visit (40+ min) | 140 | $9,114 |
2020
| Long return visit (40+ min) | 38 | $2,676 |
2019
| Return visit (30+ min) | 37 | $1,489 |
2018
| Return visit (30+ min) | 67 | $2,820 |
Drugs they prescribed that Part D paid
$422,047
Pharmacies billed $422,047 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 647) in 2024. At or below the middle of the specialty; the typical endocrinology clinician is at 0%.
368 generic and 279 brand-name prescriptions · $422,047 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Synthroid | 176 | $19,822 | $113 |
| Levothyroxine | 344 | $4,663 | $14 |
| Hydrocortisone | 19 | $2,389 | $126 |
| Liothyronine | 23 | $1,063 | $46 |
| Calcitriol | 20 | $902 | $45 |
See all 6 drugs
| Synthroid | 176 | $19,822 | $113 |
| Levothyroxine | 344 | $4,663 | $14 |
| Hydrocortisone | 19 | $2,389 | $126 |
| Liothyronine | 23 | $1,063 | $46 |
| Calcitriol | 20 | $902 | $45 |
| Methimazole | 13 | $128 | $10 |
Year by year
| 2024 | 647 | 141 | 0% (0) | 43% | $422,047 |
| 2023 | 684 | 144 | 0% (0) | 46% | $2,217,463 |
| 2022 | 676 | 150 | 0% (0) | 55% | $2,089,995 |
| 2021 | 617 | 136 | 0% (0) | 59% | $1,959,963 |
| 2020 | 586 | 118 | 0% (0) | 59% | $1,361,922 |
| 2019 | 546 | 115 | 0% (0) | 60% | $577,277 |
| 2018 | 518 | 122 | 0% (0) | 71% | $1,658,156 |
| 2017 | 634 | 144 | 0% (0) | 54% | $960,087 |
| 2016 | 717 | 113 | 0% (0) | 54% | $279,505 |
| 2015 | 266 | 80 | 0% (0) | 49% | $64,714 |
| 2014 | 267 | 76 | 0% (0) | None | $48,747 |
| 2013 | 306 | 66 | 7% (20) | None | $24,078 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Myalept | 12 | $2,165,115 | $180,426 |
| Synthroid | 172 | $20,265 | $118 |
| Levothyroxine | 352 | $6,913 | $20 |
| Hydrocortisone | 31 | $2,162 | $70 |
| Liothyronine | 16 | $809 | $51 |
| Calcitriol | 14 | $466 | $33 |
| Methimazole | 18 | $219 | $12 |
| Alendronate | 13 | $191 | $15 |
2022: 8 drugs
| Myalept | 12 | $2,042,570 | $170,214 |
| Synthroid | 155 | $17,942 | $116 |
| Levothyroxine | 358 | $7,869 | $22 |
| Tirosint | 19 | $3,966 | $209 |
| Hydrocortisone | 18 | $1,239 | $69 |
| Liothyronine | 16 | $852 | $53 |
| Methimazole | 20 | $218 | $11 |
| Levoxyl | 11 | $95 | $9 |
2021: 8 drugs
| Myalept | 12 | $1,916,188 | $159,682 |
| Synthroid | 151 | $16,186 | $107 |
| Levothyroxine | 314 | $8,227 | $26 |
| Tirosint | 17 | $3,073 | $181 |
| Hydrocortisone | 19 | $1,347 | $71 |
| Liothyronine | 22 | $1,285 | $58 |
| Calcitriol | 11 | $786 | $71 |
| Methimazole | 14 | $191 | $14 |
2020: 8 drugs
| Synthroid | 136 | $14,006 | $103 |
| Levothyroxine | 285 | $8,056 | $28 |
| Tirosint | 15 | $3,000 | $200 |
| Liothyronine | 13 | $764 | $59 |
| Calcitriol | 13 | $755 | $58 |
| Hydrocortisone | 12 | $735 | $61 |
| Alendronate | 23 | $278 | $12 |
| Methimazole | 16 | $165 | $10 |
2019: 6 drugs
| Synthroid | 130 | $10,527 | $81 |
| Levothyroxine | 264 | $7,070 | $27 |
| Tirosint | 20 | $4,116 | $206 |
| Methimazole | 14 | $301 | $21 |
| Alendronate | 22 | $208 | $9 |
| Metformin | 14 | $127 | $9 |
2018: 8 drugs
| Myalept | 13 | $1,572,154 | $120,935 |
| Synthroid | 96 | $7,689 | $80 |
| Levothyroxine | 266 | $6,430 | $24 |
| Novolog | 11 | $6,261 | $569 |
| Tirosint | 17 | $2,777 | $163 |
| Desmopressin Acetate | 12 | $1,375 | $115 |
| Hydrocortisone | 11 | $932 | $85 |
| Metformin | 11 | $153 | $14 |
2017: 10 drugs
| Forteo | 25 | $76,071 | $3,043 |
| Humalog Kwikpen U-100 | 18 | $18,737 | $1,041 |
| Novolog | 14 | $9,868 | $705 |
| Levothyroxine | 239 | $4,961 | $21 |
| Synthroid | 59 | $4,264 | $72 |
| Ultra-Fine Nano Pen Needle | 22 | $2,033 | $92 |
| Desmopressin Acetate | 12 | $1,286 | $107 |
| Hydrocortisone | 19 | $1,116 | $59 |
| Methimazole | 44 | $524 | $12 |
| Alendronate | 15 | $109 | $7 |
2016: 19 drugs
| Humalog Kwikpen U-100 | 54 | $47,828 | $886 |
| Humulin R U-500 | 11 | $27,617 | $2,511 |
| Novolog Flexpen | 27 | $24,927 | $923 |
| Humalog | 21 | $20,967 | $998 |
| Tresiba Flextouch U-200 | 13 | $14,715 | $1,132 |
| Lantus Solostar | 25 | $13,787 | $551 |
| Lantus | 13 | $7,961 | $612 |
| Humalog Mix 75-25 | 14 | $7,065 | $505 |
| Toujeo Solostar | 11 | $4,386 | $399 |
| Bd Ultra-Fine Pen Needle | 49 | $4,336 | $88 |
| Synthroid | 45 | $2,224 | $49 |
| Desmopressin Acetate | 11 | $2,008 | $183 |
| Metformin Hcl Er | 12 | $1,998 | $167 |
| Levothyroxine | 112 | $1,944 | $17 |
| Hydrocortisone | 19 | $681 | $36 |
| Metformin | 29 | $332 | $11 |
| Methimazole | 25 | $286 | $11 |
| Alendronate | 16 | $116 | $7 |
| Glipizide | 18 | $67 | $4 |
2015: 6 drugs
| Humalog | 11 | $9,669 | $879 |
| Synthroid | 23 | $1,740 | $76 |
| Levothyroxine | 59 | $1,626 | $28 |
| Prednisone | 11 | $181 | $16 |
| Glimepiride | 16 | $178 | $11 |
| Metformin | 12 | $134 | $11 |
2014: 7 drugs
| Novolog Flexpen | 11 | $4,360 | $396 |
| Tirosint | 17 | $1,184 | $70 |
| Synthroid | 17 | $975 | $57 |
| Levothyroxine | 37 | $882 | $24 |
| Hydrocortisone | 12 | $411 | $34 |
| Glimepiride | 24 | $310 | $13 |
| Alendronate | 15 | $111 | $7 |
2013: 5 drugs
| Nexium | 11 | $6,710 | $610 |
| Atorvastatin | 12 | $429 | $36 |
| Fluticasone Propionate | 13 | $306 | $24 |
| Levothyroxine | 26 | $230 | $9 |
| Metoprolol | 19 | $95 | $5 |
Money from drug and device companies
$281 in 2025
| 2025 | 2 | 2 | None | $281 |
| 2024 | 1 | 1 | None | $47 |
| 2023 | 3 | 4 | $918 | $1,124 |
| 2019 | 3 | 3 | None | $210 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Dilon Technologies | Hemoblast Bellows | $168 | 1 payment
|
| Amgen | Tepezza | $113 | 1 payment
|
See all 2 published payments
| Amgen | Meals · 2025-09-13 | Tepezza | $113 |
| Dilon Technologies | Meals · 2025-05-09 | Hemoblast Bellows | $168 |
See earlier years (2024, 2023, 2019)
2024: $47
| Amgen | Tepezza | $47 | 1 payment
|
2023: $1,124
| Bayer Healthcare Pharmaceuticals | Vitrakvi | $918 | 1 payment
|
| Horizon Therapeutics plc | Tepezza | $118 | 1 payment
|
| Acella Pharmaceuticals | NP Thyroid 60 | $89 | 2 payments
|
2019: $210
| AbbVie | Synthroid | $102 | 1 payment
|
| Dexcom | Dexcom Cgm | $57 | 1 payment
|
| Senseonics | Eversense | $51 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1316266778
- Licence
- CA A145417, SC 38745California A145417: Current · expires 2026-10-31
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- SC 387450
- Taxonomy
- Federal specialty code 207RE0101X (207RE0101X)
- Mailing address
- 300 Pasteur Dr, Palo Alto, CA, 94304
- NPI first listed
- 2010-05-25
- NPI last updated
- 2024-04-28
- NPI record certified
- 2024-04-28
This is when the NPI record was last certified, not a medical board exam.